Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROTATE-2
2017-001977-18Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- May 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of telmisartan, empagliflozin, linagliptin and baricitinib in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Reduction in albuminuria. Started May 2017; status: completed.
02
Drugs
telmisartanempagliflozinlinagliptinbaricitinib
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-001977-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001977-18.